Invasive aspergillosis in hematologic pediatric patients is an opportunistic infection that is difficult to treat, with a high mortality rate when localized in the central nervous system. We are describing a 3-year-old girl who was affected by acute lymphoblastic leukemia who developed cerebral and pulmonary aspergillosis during induction chemotherapy. The patient failed first-line voriconazole treatment because of being a CYP2C19 ultrarapid metabolizer and received effective isavuconazole therapy with no notable side effects.
*Department of Pediatrics, Division of Pediatric Hematology-Oncology
†Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari
‡IRCCS Istituto Giannina Gaslini, Children’s Hospital, Genova, Italy
No support was received from NIH, HHMI, or others (pharmaceutical, industries etc.).
The authors declare no conflict of interest.
Reprints: Francesco De Leonardis, MD, PhD, Department of Pediatrics, Division of Pediatric Hemathology-Oncology, Piazza G. Cesare 11, Bari 70124, Italy (e-mail: email@example.com).
Received December 28, 2018
Accepted April 6, 2019